drugset / Trial / NCT07826533

Intravenous Papaverine for Term Prelabor Rupture of Membranes

NCT07826533 ↗

Recruiting 200 enrolled Wolfson Medical Center
RandomizedParallel-groupDouble-blindTreatment

Summary

This randomized, double-blind, placebo-controlled trial evaluates whether intravenous papaverine, administered as an adjunct to oxytocin, shortens the time to delivery in women with term premature rupture of membranes (PROM). Participants are randomized in a 1:1 ratio to receive either intravenous papaverine 80 mg in 100 mL of 0.9% saline or 100 mL of 0.9% saline as placebo, administered one hour after initiation of oxytocin. The primary outcome is the interval from study infusion to delivery. Secondary outcomes include mode of delivery and maternal and neonatal outcomes.

Timeline

Start
2025-03-20
Primary completion
2027-04-21
Completion
2027-04-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Papaverine Small molecule 80 mg Intravenous